Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review

BACKGROUND: In 2007, Canada chose to develop a separate and distinct path for oncology drug health technology assessment (HTA). In 2013, the decision was made to transfer the pan-Canadian Oncology Drug Review (pCODR) to the Canadian Agency for Drugs and Technologies in Health (CADTH), to align the p...

Descripción completa

Detalles Bibliográficos
Autores principales: Rocchi, Angela, Chabot, Isabelle, Glennie, Judith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461134/
https://www.ncbi.nlm.nih.gov/pubmed/26082654
http://dx.doi.org/10.2147/CEOR.S82549

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461134/
https://www.ncbi.nlm.nih.gov/pubmed/26082654
http://dx.doi.org/10.2147/CEOR.S82549

Ejemplares similares